CRBP return to pre-covid?
Обновлено
The stock has been above $5 most of the time.
It is only that Lenbasaum, their leading drug, has failed in one of the clinical studies, that is why the stock plummeted in Sep 2020.
Nonetheless, they have couple others ongoing studies and they may have a chance to recover to pre-covid levels.
Before the September news their ratings were Buy and Outperform at $12, $22 and even $40 levels.
Mind the fundamentals and news.
It is only that Lenbasaum, their leading drug, has failed in one of the clinical studies, that is why the stock plummeted in Sep 2020.
Nonetheless, they have couple others ongoing studies and they may have a chance to recover to pre-covid levels.
Before the September news their ratings were Buy and Outperform at $12, $22 and even $40 levels.
Mind the fundamentals and news.
Комментарий
Idea workedAnd it may still have some potential
Отказ от ответственности
Все виды контента, которые вы можете увидеть на TradingView, не являются финансовыми, инвестиционными, торговыми или любыми другими рекомендациями. Мы не предоставляем советы по покупке и продаже активов. Подробнее — в Условиях использования TradingView.